A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

October 27, 2021

Primary Completion Date

October 15, 2024

Study Completion Date

October 15, 2024

Conditions
MelanomaCarcinoma, HepatocellularColorectal Neoplasms
Interventions
DRUG

E7386

E7386 tablet.

DRUG

Pembrolizumab

Pembrolizumab IV infusion.

DRUG

Lenvatinib

Lenvatinib capsule.

Trial Locations (33)

10029

Icahn School of Medicine at Mount Sinai, New York

30322

Emory University, Atlanta

33401

SCRI Florida Cancer Specialists East, West Palm Beach

33916

Florida Cancer Specialists, Fort Myers

37203

Sarah Cannon Cancer Care in Nashville, Nashville

48201

Barbara Ann Karmanos Cancer Center, Detroit

90024

University of California, Los Angeles, Los Angeles

92868

University of California, Irvine Health, Orange

97213

Providence Medical Center, Portland

08901

Rutgers cancer Institute of NJ, New Brunswick

Unknown

Chiba University Hospital, Chiba

National Cancer Center Hospital, Chūōku

Kurume University Hospital, Fukuoka

National Cancer Center Hospital East, Kashiwa

Kindai University Hospital, Osaka

Osaka Metropolitan University Hospital, Osaka

Sapporo-Kosei General Hospital, Sapporo

Shizuoka Cancer Center Hospital, Shizouka

Toranomon Hospital, Tokyo

Hospital Regional Universitario de Malaga, Málaga

Hospital Clínico San Carlos, Madrid

Clínica Universidad de Navarra, Pamplona

Hospital Universitario de Badajoz, Badajoz

Hospital Clinic de Barcelona, Barcelona

Hospital Universitari Vall d'Hebron, Barcelona

Hospital General Universitario Gregorio Maranon, Madrid

Hospital Universitario de la Paz, Madrid

Consorcio Hospital General Universitario de Valencia, Valencia

The Royal Marsden NHS Foundation Trust - The Royal Marsden Hospital, Sutton

Beatson West of Scotland Cancer Centre, Glasgow

Imperial College London, London

Royal Free Hospital NHS Foundation Trust, London

The Christie NHS Foundation Trust, Manchester

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT05091346 - A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | Biotech Hunter | Biotech Hunter